Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols (reductive 3a.HSO) CYP17A1 (reductive 3a.HSD) CYP17A1 (oxidative 3a.HSO) AKRIC AKRICI

div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divpAbiraterona en CPRCAbiraterona en CPRCpdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 4button div class=ts-image amp-img class=ts-thumb alt=Page 4: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 5button div class=ts-image amp-img class=ts-thumb alt=Page 5: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails5jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 6button div class=ts-image amp-img class=ts-thumb alt=Page 6: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails6jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 7button div class=ts-image amp-img class=ts-thumb alt=Page 7: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails7jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 8button div class=ts-image amp-img class=ts-thumb alt=Page 8: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails8jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 9button div class=ts-image amp-img class=ts-thumb alt=Page 9: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails9jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 10button div class=ts-image amp-img class=ts-thumb alt=Page 10: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails10jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 11button div class=ts-image amp-img class=ts-thumb alt=Page 11: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails11jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 12button div class=ts-image amp-img class=ts-thumb alt=Page 12: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails12jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 13button div class=ts-image amp-img class=ts-thumb alt=Page 13: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails13jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 14button div class=ts-image amp-img class=ts-thumb alt=Page 14: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails14jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 15button div class=ts-image amp-img class=ts-thumb alt=Page 15: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails15jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 16button div class=ts-image amp-img class=ts-thumb alt=Page 16: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails16jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 17button div class=ts-image amp-img class=ts-thumb alt=Page 17: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails17jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 18button div class=ts-image amp-img class=ts-thumb alt=Page 18: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails18jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 19button div class=ts-image amp-img class=ts-thumb alt=Page 19: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails19jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 20button div class=ts-image amp-img class=ts-thumb alt=Page 20: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails20jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 21button div class=ts-image amp-img class=ts-thumb alt=Page 21: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails21jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 22button div class=ts-image amp-img class=ts-thumb alt=Page 22: Abiraterona en CPRC · x 2 Aldosterone ACTH Prednisona + SEOM UGT2B15 UGT2B17 CYP7B1 a-Triols reductive 3aHSO CYP17A1 reductive 3aHSD CYP17A1 oxidative 3aHSO AKRIC AKRICI src=https:reader033vdocumentscoreader033viewer20220422175ec0eb3b0bacc6609823bfc2html5thumbnails22jpg width=142 height=106 layout=responsive amp-img divpAbiraterona en CPRCAbiraterona en CPRCpdiv

abiraterona en cprc · x 2 aldosterone acth prednisona + seom ugt2b15 ugt2b17 cyp7b1 a-triols...

Documents

soraya mora romero, gema morcillo...

mª josé vázquez hospital de móstoles …resistente a...

ikastorratza. e-journal on didactics · propuesta para una...

abiraterona y cabazitaxel en cáncer de próstata...

abiraterona -...

oxidative stress in staphylococcus aureus treated with

abiraterona en pacientes de edad avanzada · para evaluar...

protein damage by oxidative stress - upv/ehu · xabi eta...

abiraterona · web viewen la curva de sg se alcanzó una...

¿cÓmo separan y ordenan las acepciones los … ·...

tratamiento del cáncer de próstata resistente a la ... ·...

laboratorio de análisis clínicos en vilagarcía -...

medicina de precisión en el cáncer de próstata€¦ ·...

colorectal tumors require nuak1 for protection from...

tema 27 - universidad de alcalá (uah) madrid · tema 27...

oxyresveratrol inhibits cellular tyrosinase-related...

coaching con...

novedades en el manejo del paciente con cprc m0 y su...

cprc: cprc m0, opciones terapéuticas...papel de distintas...

17β-estradiol and testosterone protect …actualizaciones...